Spots Global Cancer Trial Database for dalotuzumab
Every month we try and update this database with for dalotuzumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) | NCT00635778 | Advanced Solid ... | dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) | NCT01243762 | Neoplasms Malig... | dalotuzumab MK-0752 ridaforolimus MK-2206 | 18 Years - | Merck Sharp & Dohme LLC | |
| Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | NCT00701103 | Solid Tumor Multiple Myelom... | Dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | NCT00701103 | Solid Tumor Multiple Myelom... | Dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) | NCT00654420 | Carcinoma, Non-... | Dalotuzumab Erlotinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | NCT01605396 | Breast Neoplasm... | Ridaforolimus Dalotuzumab Exemestane | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | NCT01609231 | Rectal Neoplasm... | Dalotuzumab Irinotecan Cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00951444 | Lung Cancer | dalotuzumab carboplatin gemcitabine hyd... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009) | NCT00694356 | Neoplasm | Dalotuzumab | 20 Years - | Merck Sharp & Dohme LLC | |
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) | NCT01605396 | Breast Neoplasm... | Ridaforolimus Dalotuzumab Exemestane | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) | NCT00614393 | Metastatic Colo... | dalotuzumab irinotecan hydr... cetuximab placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00951444 | Lung Cancer | dalotuzumab carboplatin gemcitabine hyd... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) | NCT01431547 | Solid Tumors | dalotuzumab dalotuzumab ridaforolimus | 3 Years - 17 Years | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
